Latest Commercial Strategy News

Skin Elements is poised to commercialise five natural biotechnology products after successful evaluations, while navigating cashflow pressures and upcoming shareholder votes on board control.

First Graphene bolsters its market position through strategic acquisitions and a pioneering UK trial of graphene-enhanced cement roof tiles, while securing new distribution deals across key international markets.

HeraMED pushes forward in the US market, progressing its Philips partnership into active sales and scaling its Lee Health pilot to 2,000 pregnancies, underpinned by a recent $3.2 million capital raise.

Blue Star Helium has completed Stage 1 of its Galactica development, tying six wells into the Pinon Canyon facility and starting spot-priced helium sales. The company raised A$10 million to fund further project expansion and working capital.

Alterity Therapeutics secures FDA backing on key Phase 3 elements for ATH434 in Multiple System Atrophy, bolstered by fresh Phase 2 data showing slowed disease progression and strategic leadership hires.

Prairie Lithium has moved Pad #1 from groundwork to active building construction, backed by SaskPower's powerline installation and a binding Hydro Lithium offtake agreement that includes a A$10 million equipment contribution. First production is targeted for Q4 2026.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.

Racura Oncology reported robust progress in Q3 FY2026, including launching a key lung cancer trial and unveiling a novel blood test for cardioprotection, supported by a solid $19.38 million cash position.

Optiscan Imaging has submitted its FDA dossier for InSpecta®, marking a crucial step toward US veterinary market entry, while progressing clinical studies for InVue® and InForm® ahead of further FDA submissions in 2026.

Syntara Limited has raised A$10 million through a two-tranche placement and share purchase plan, backing its Phase 2b myelofibrosis trial and multiple clinical readouts following positive FDA feedback.

PTR Minerals delivered standout assay results from its Rosewood Titanium Project, confirming extensive high-grade mineralisation and strong metallurgical performance, keeping its maiden JORC resource estimate on track for Q2 2026.

Avecho Biotechnology has exceeded its Phase III CBD insomnia trial recruitment target by 16%, setting the stage for a more robust interim analysis scheduled for June 2026. The company’s commercial partnership with Sandoz AG and strengthened patent portfolio underpin its Australian market strategy.